Benefits
Testosterone increase in middle-aged men
A 2016 randomized double-blind placebo-controlled trial in 75 healthy men aged 45-55 showed purified shilajit at 500 mg/day for 90 days increased total testosterone ~20%, free testosterone ~19%, and DHEAS significantly. LH and FSH remained stable — suggesting Leydig cell stimulation rather than HPA-axis disruption. Important caveat: the trial used the PrimaVie® branded form and was partially manufacturer-funded.
Mitochondrial energy and CoQ10 potentiation
Shilajit's DBPs are mitochondrial electron carriers that may enhance ATP production. A small trial in physically active men showed positive trends in muscle strength and mitochondrial function. Animal evidence suggests shilajit may potentiate CoQ10's effects on cellular energy metabolism, though human confirmation is limited.
Mineral absorption and bioavailability
Fulvic acid's chelating structure may enhance absorption of minerals and other nutrients across cell membranes. Indian medical literature shows shilajit supplementation improves hemoglobin and ferritin in anemic patients. Practical relevance for those with poor mineral status from diet or absorption issues.
Muscle strength and exercise performance (preliminary)
Trials in active men suggest shilajit at 500 mg/day may preserve muscle strength during training and support recovery. Effect sizes are modest and not all trials reach statistical significance — promising preliminary evidence rather than well-established effect.
Cognitive support (preliminary)
Animal and in vitro studies show fulvic acid inhibits tau protein aggregation (relevant to Alzheimer's pathology). Human cognitive evidence is limited to small preliminary trials. Promising mechanistic rationale but not yet validated in robust human trials.
Honest counter-evidence and limitations
Most positive trials used the PrimaVie® branded form with partial manufacturer funding — meaningful but not independent confirmation. Sample sizes are small (under 100 participants typically). Independent reviewers including Hims have characterized the testosterone evidence as 'not enough to establish' rather than confirmatory. Larger independently-funded trials are needed.
Heavy metal safety — critical purification
Raw unprocessed shilajit can contain lead, arsenic, mercury, mycotoxins, and free radicals from its geological source. The purification process determines whether shilajit is therapeutic or toxic. Always choose third-party tested products with documented heavy metal certificates of analysis. Cheap unverified shilajit products are a real safety concern, not theoretical.
Mechanism of action
Mitochondrial electron transport chain support
Dibenzo-α-pyrones (DBPs) in shilajit function as endogenous mitochondrial electron carriers — similar in mechanism to CoQ10 but structurally distinct. They facilitate electron transfer in Complex I and II of the respiratory chain, improving ATP production efficiency and reducing reactive oxygen species leakage from the electron transport chain.
Fulvic acid antioxidant and chelation
Fulvic acid is a low-molecular-weight humic substance with exceptional free radical scavenging capacity and metal-chelating properties. It donates electrons to neutralize reactive oxygen species, chelates redox-active metals (iron, copper) to prevent Fenton-type hydroxyl radical generation, and crosses cell membranes to deliver antioxidant protection intracellularly.
Tau aggregation inhibition and neuroprotection
Fulvic acid directly inhibits tau protein self-aggregation and disrupts preformed tau fibrils — the neurofibrillary tangles associated with Alzheimer's disease progression. This mechanism, demonstrated in cell culture and animal models, positions shilajit as a potential neuroprotective ingredient for cognitive aging applications.
Clinical trials
Randomized, double-blind, placebo-controlled trial. 96 healthy men aged 45-55 randomized to 250 mg PrimaVie® twice daily (500 mg/day total) or placebo × 90 days.
96 healthy men aged 45-55
Randomized, double-blind, placebo-controlled trial. 96 healthy men aged 45-55 randomized to 250 mg PrimaVie® twice daily (500 mg/day total) or placebo × 90 days. Total testosterone +20.45% (398.8 → 474.91 ng/dL, p<0.05). Free testosterone +19.14%. DHEAS significantly increased. LH and FSH maintained, suggesting peripheral testicular effect rather than HPG axis stimulation. Conducted at J.B. Roy State Ayurvedic Medical College, Kolkata.
Open-label trial in 28 oligospermic men, 100 mg purified shilajit twice daily × 90 days.
Clinical population described in trial publication.
Open-label trial in 28 oligospermic men, 100 mg purified shilajit twice daily × 90 days. Total sperm count +61.4%, sperm concentration +37.6%, motility +12-17% (depending on time-point), normal morphology +18.9%, all p<0.001 vs. baseline. Total testosterone +23.5%. Limitations: single-arm open-label design (no placebo), single research group, n=28. Should be interpreted with caution despite striking effect sizes.
Clinical trial in 63 recreationally active men aged 21-50.
Clinical population described in trial publication.
Clinical trial in 63 recreationally active men aged 21-50. Randomized to 250 mg, 500 mg PrimaVie®, or placebo × 8 weeks during a structured resistance training program. 500 mg group showed better preservation of maximal voluntary isometric contraction (MVIC) strength after fatigue protocol. Reduced exercise-induced hydroxyproline (collagen breakdown marker). Effect attributed to mitochondrial bioenergetics support.
Phase II multicenter randomized, double-blind, placebo-controlled clinical trial.
82 patients with mild-to-moderate Alzheimer's disease
Phase II multicenter randomized, double-blind, placebo-controlled clinical trial. 82 patients with mild-to-moderate Alzheimer's disease randomized to BrainUp-10® (shilajit + B-complex vitamins) or placebo. Significant improvements in apathy and cognitive stability. Important caveat: this is a combination product (shilajit + B vitamins), not shilajit alone — effects cannot be attributed solely to shilajit. Independent shilajit-monotherapy trials in cognitive endpoints are limited.